Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VOR
STRONG SELLVor Biopharma Inc. · Healthcare · United States · $1.0B · Avg Vol: $30M/d
COMPANY DESCRIPTION
Vor Biopharma is a clinical-stage biotechnology company developing engineered hematopoietic stem cell (eHSC) therapies for blood cancers. Its proprietary eHSC platform aims to enable targeted therapies post-transplant, addressing a significant unmet medical need. This focus on immuno-oncology and cell therapy offers a potential competitive advantage in a rapidly evolving treatment landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -2.84 | -2.19 | -3.92 | -70.50 | — | -67.95 |
| Shares | 54.2M | 54.2M | 54.2M | 38.7M | -28.5% | — |
| Debt | 38.9M | 35.7M | 31.8M | 3.0M | -57.4% | 2.9M |
| Equity | 250.6M | 150.7M | 96.7M | -164.3M | -37.9% | — |
| Op CF | -85.1M | -100.3M | -99.7M | -142.7M | — | -149.9M |
| Inv CF | -94.1M | 71.0M | 96.9M | -48.8M | — | — |
| Fin CF | 117.1M | 2.9M | 53.4M | 503.8M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VOR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc.(you) | $1.0B | 14 | STRONG SELL |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.1B | 11 | STRONG SELL |
| OLMA | Olema Pharmaceuticals, Inc. | $1.0B | 10 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 18 | STRONG SELL |
| INBX | Inhibrx Biosciences, Inc. | $1.2B | 10 | STRONG SELL |
| ANNX | Annexon, Inc. | $855M | 16 | STRONG SELL |
| SVRA | Savara Inc. | $1.1B | 19 | STRONG SELL |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 8 | STRONG SELL |
| SANA | Sana Biotechnology, Inc. | $885M | 9 | STRONG SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 19 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%